Gilead Announces that USPTO to Uphold One of the Viread Patents

22 May 2008

Reuters and Forbes have run reports that Gilead has received news that one of its four Viread related patents has been re-affirmed as valid following earlier requests for re-examination.

The USPTO has yet to update the status of any of the patents that were re-examined, so we await to see whether it will be the one of the three ester derivative patents (Tenofovir Disoproxil) or the end formulation (Tenofovir Disoproxil Fumarate). We suspect it may be the ester derivative patent, but will update this post once we have more news.

Join us to stay updated
and help make lifesaving medicines accessible to all